Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Redhill Biopharma
Redhill Biopharma logo

RDHL - Redhill Biopharma Share News

$9.94 -0.3  -2.6%

Last Trade - 9:00pm

Sector
Healthcare
RiskRating
Adventurous
Size
Small Cap
Style
Momentum Trap
Market Cap £254.7m
Enterprise Value £290.8m
Revenue £31.5m
Position in Universe 3861st / 6713
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions RDHL Dividends
All News
All News Reuters News Company Announcements
BRIEF-Redhill Biopharma Announces Planned Expansion Of Opaganib Global Phase 2/3 Covid-19 Study To The U.S.
Tue 12:26pm News
BRIEF-Redhill Biopharma Announces Agreements With Cosmo Pharmaceuticals NV To Manufacture Movantik And RHB-204
18th Feb News
BUZZ-RedHill Biopharma: Rises as first patient dosed in U.S. COVID-19 drug study
17th Feb News
BRIEF-RedHill Biopharma Announces First Patient Dosed In U.S. Phase 2/3 COVID-19 Outpatient Study With RHB-107
17th Feb News
BUZZ-RedHill Biopharma: Up as independent panel supports COVID-19 drug trial
29th Jan News
BUZZ-RedHill Biopharma: Rises on manufacturing deal for COVID-19 treatment
28th Jan News
BRIEF-Redhill Biopharma Further Expands Opaganib Manufacturing Capacity For Covid-19 With Cosmo Pharmaceuticals
28th Jan News
BRIEF-RedHill Partner Cosmo Pharmaceuticals Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
11th Jan News
BUZZ-RedHill: Up on fast track status for lung disease treatment
6th Jan News
BRIEF-Redhill Biopharma's RHB-204 Granted FDA Fast Track Designation For NTM Disease
6th Jan News
BRIEF-Redhill Biopharma Announces Positive Top-Line Safety And Efficacy Data From Phase 2 COVID-19 Study Of Opaganib
31st Dec '20 News
BRIEF-RedHill's Phase 2/3 COVID-19 Study Of Opaganib Passes Second DSMB With Unanimous Recommendation To Continue
22nd Dec '20 News
BRIEF-Redhill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting In Preclinical Model
15th Dec '20 News
BRIEF-Redhill Biopharma Ltd Says Selected For Addition To Nasdaq Biotechnology Index
14th Dec '20 News
BRIEF-RedHill Biopharma Increases Unrestricted National, Regional Commercial Coverage For Talicia To Over 40 Mln Additional Americans
7th Dec '20 News
BUZZ-RedHill: Rises on U.S. deals to ramp up manufacturing of COVID-19 treatment
25th Nov '20 News
BRIEF-Redhill Biopharma Expands U.S.-Based Manufacturing Capacity Of Opaganib For Covid-19
25th Nov '20 News
BRIEF-Redhill Biopharma Initiates Phase 3 Study Of RHB-204 For First-Line Treatment Of NTM Disease
20th Nov '20 News
BRIEF-RedHill Announces Unanimous Dsmb Recommendation To Continue Phase 2/3 COVID-19 Study With Opaganib
19th Nov '20 News
BUZZ-RedHill Biopharma: Up on safety panel nod to continue COVID-19 treatment study
19th Nov '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.